Rheumatoid arthritis (RA) is an autoimmune disease that involves multiple joints bilaterally.
It is characterized by an inflammation of the tendon (tenosynovitis) resulting in both cartilage …

Approximately one in four patients treated with anti-TNF agents (infliximab, etanercept,
adalimumab, certolizumab, and golimumab) develops cutaneous adverse events, typically …

Background Infliximab (IFX) combined with azathioprine (AZA) is more effective than IFX
monotherapy in inflammatory bowel disease (IBD). Aim To identify the AZA optimal dose that …

Immune checkpoint inhibitors (ICI) significantly improve overall survival (OS) in patients with
advanced melanoma, but immune-related colitis may occur and warrant anti-tumor necrosis …

Objective: Skin cancer is one of the most common cancers in the world, ranking first in men
and second in women. The aim of this study was to determine the incidence and prevalence …

BACKGROUND Azathioprine and 6-mercaptopurine (thiopurines) are common adjunct
treatments for inflammatory bowel disease (IBD). Although thiopurine therapy in organ …

Tumor necrosis factor (TNF)-α has been identified as a key cytokine mediating cutaneous
inflammation in the pathogenesis of psoriasis. The TNF inhibitors (TNFi's) infliximab …

Simple Summary Tumor necrosis factor (TNF) and its closely related cytokine, lymphotoxin
alpha (LTα), are part of the TNF superfamily and exert their functions via both overlapping …

Inflammatory bowel diseases are chronic conditions of unknown etiology, showing a
growing incidence and prevalence in several countries, including Italy. Although the etiology …

Background We compared risks of nonmelanoma skin cancers (NMSCs) and melanoma
preceding and following a diagnosis of inflammatory bowel disease (IBD) and to evaluate …